Clinical Trials

228 enrolled

Multiple Myeloma, Recurrence

NCT05911321 2026-05-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

6 enrolled 5 charts

Multiple Myeloma, Recurrence

NCT06615479 2026-05-13

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Multiple Myeloma, Recurrence

NCT07579234 2026-05-12

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

261 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02343042 2026-05-04

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT05455320 2026-04-13

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT05552976 2026-04-01

SUCCESSOR-2

606 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT04756726 2026-03-25

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

224 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Phase 1/2 Active not recruiting

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT01615029 2026-03-16

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Phase 1/2 Completed

45 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT05530421 2026-02-23

SELVEDge

33 enrolled

Multiple Myeloma, Recurrence

NCT03374085 2026-02-09

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Phase 1/2 Terminated

200 enrolled

Multiple Myeloma, Recurrence

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

52 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT01562405 2026-01-14

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

33 enrolled

Multiple Myeloma, Recurrence

NCT05922501 2026-01-14

ISABELA

50 enrolled

Multiple Myeloma, Recurrence

NCT02461888 2025-12-17

MUKEight

112 enrolled

Multiple Myeloma, Recurrence

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Phase 1/2 Recruiting

49 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

43 enrolled

Multiple Myeloma, Recurrence

NCT07018050 2025-09-22

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

160 enrolled

Multiple Myeloma, Recurrence

NCT04191616 2025-09-04

SELECT

54 enrolled 17 charts

Multiple Myeloma, Recurrence

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

120 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed

7 enrolled

Multiple Myeloma, Recurrence

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms, Recurrence

NCT02332850 2025-05-01

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

83 enrolled

Multiple Myeloma, Recurrence

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Phase 1/2 Terminated

14 enrolled

Multiple Myeloma, Recurrence

NCT01903811 2024-12-20

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

143 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT06561854 2024-12-18

FREEDOM

318 enrolled

Multiple Myeloma, Recurrence

NCT03836014 2024-12-06

CONFIRM

436 enrolled

Multiple Myeloma, Recurrence

NCT02406222 2024-12-05

MUKseven

124 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled

Multiple Myeloma, Recurrence

NCT06050512 2024-11-19

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT00482261 2024-11-08

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

150 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02939183 2024-09-26

INTREPID-1

Phase 1 Completed

61 enrolled 28 charts

Multiple Myeloma, Recurrence

NCT02616640 2024-09-19

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 1 Completed

114 enrolled

402 enrolled 22 charts 1 FDA

Multiple Myeloma, Recurrence

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

Multiple Myeloma, Recurrence

NCT03859427 2024-08-13

ARROW2

Phase 3 Completed

454 enrolled 24 charts

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT02654990 2024-07-12

PANORAMA_3

248 enrolled 28 charts

Multiple Myeloma, Recurrence

NCT06232707 2024-05-31

ALUMMINATE

Phase 3 Withdrawn

Multiple Myeloma, Recurrence

NCT03450057 2024-03-29

DARE

38 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

4 enrolled

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT01913730 2023-12-13

Maintenance Therapy With Subcutaneous Bortezomib

63 enrolled

Multiple Myeloma, Recurrence

NCT05647512 2023-11-18

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

45 enrolled

Multiple Myeloma, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

45 enrolled

Multiple Myeloma, Recurrence

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Phase 1 Terminated

8 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT03439280 2023-02-24

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Phase 1/2 Completed

50 enrolled 26 charts

Multiple Myeloma, Recurrence

NCT02807454 2023-02-21

FUSIONMM-003

Phase 2 Terminated

37 enrolled 21 charts

Multiple Myeloma, Recurrence

NCT05408026 2023-01-27

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Phase 1/2 Withdrawn